July 27, 2015Current Medical Research and Opinion

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications

View Full Paper

Ask AI

Bookmark

Why the study?

Does rivaroxaban improve medication adherence compared to dabigatran and apixaban in adult chronic NOAC users?

Population

9,948 adults who were chronic users of non-vitamin-K-antagonist oral anticoagulants with ≥2 dispensings ≥180…

Comparison

Rivaroxaban vs Dabigatran and apixaban

Design

Cohort

Authors

CCConcetta CriveraJohnson & Johnson (United States)WNWinnie W. NelsonHelsinn Therapeutics (United States)BBBrahim BookhartJohnson & Johnson (United States)

Discussion

Member takes

Implication

Rivaroxaban shows higher PQA-measured adherence than other NOACs in claims data; leaves open effects on outcomes or performance-measure adoption.

Structured PICO

Does rivaroxaban improve medication adherence compared to dabigatran and apixaban in adult chronic NOAC users?

Population

9,948 adults (>18 years) who were chronic users of non-vitamin-K-antagonist oral anticoagulants (NOACs) with ≥2 dispensings ≥180 days apart, ≥60 days of supply, and ≥180 days of continuous enrollment prior to index NOAC.

Intervention

Rivaroxaban

Comparator

Dabigatran and apixaban

Outcome

Adherence based on the Pharmacy Quality Alliance (PQA) measure (percentage of patients with a proportion of days covered [PDC] ≥0.8 during follow-up)

Real-world claims data suggest that patients prescribed rivaroxaban have higher adherence rates compared to those prescribed dabigatran or apixaban based on the PQA measure.

Limitations

Claims data may have contained inaccuracies
Possible change in patterns over time
Impossibility of knowing whether all supplied tablets were taken

Cite This Study

Crivera et al. (2015) studied this question.

synapsesocial.com/papers/6a760363f1e99ff85ab22c64 https://doi.org/10.1185/03007995.2015.1077213

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

Rivaroxaban shows higher PQA-measured adherence than other NOACs in claims data; leaves open effects on outcomes or performance-measure adoption.

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider